Sunday, April 07, 2013 1:19:26 PM
We have made a diligent effort since founding to find a facility where we could get our drugs made without going through the time and expense of building one ourselves. Our nanoviricides® drugs are defining the cutting edge of pharmaceutical technology. Such products have never been made before in the pharmaceutical arena as drugs. Thus we found that the expertise for translating our technology into a manufacturing process with appropriate controls is rare in contract manufacturing organizations (CMOs). In addition, our negotiations with certain CMOs demonstrated to us that any CMO would need to put in specialized equipment for our processes, and the cost of the equipment design and engineering, process design and engineering, as well as the cost of all custom modifications to their facilities and the custom equipment, would be passed on to NanoViricides, Inc. We also found out that a small nimble company like ours can find ways to do these things at a much lower cost than a medium or large CMO.
If they had "all the money in the world" they absolutely could get a manufacturing facility operational faster. To claim otherwise is more "NNVC exceptionalism" and completely false.
I think all the talk of China is ridiculous and I put it in the same group as the Hawaii party menu planning discussion from 3 years ago, $100 SP and 40 virgins waiting in heaven. Just more Soma.
Let's just get tox and facility done before the end of '14.
Publishing some results now that they have an "affiliation" with The Center for Biological Physics and California NanoSystems Institute would do wonders for PR and the SP. But unlikely until phase 1 is complete ('15 at the earliest).
Recent NNVC News
- Form 8-K - Current report • Edgar (US Regulatory) • 08/09/2024 08:30:39 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 08/09/2024 08:05:25 PM
- NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • InvestorsHub NewsWire • 05/02/2024 02:07:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:53:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 09:55:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 09:44:48 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 12/04/2023 09:08:49 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 10/13/2023 08:30:41 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 09/28/2023 08:44:54 PM
FEATURED Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM
North Bay Resources Announces Mt. Vernon Gold Mine Bulk Sample, Sierra County, California • NBRI • Sep 11, 2024 9:15 AM
One World Products Issues Shareholder Update Letter • OWPC • Sep 11, 2024 7:27 AM
Kona Gold Beverage Inc. Reports $1.225 Million in Revenue and $133,000 Net Profit for the Quarter • KGKG • Sep 10, 2024 1:30 PM
Element79 Gold Corp Announces 2024 Clover Work Plans & Nevada Portfolio Updates • ELMGF • Sep 10, 2024 11:00 AM